olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
Published 2 years ago • 445 plays • Length 3:41Download video MP4
Download video MP3
Similar videos
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
5:36
propel trial
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
6:39
latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
5:12
magnitude shows benefit of add-on niraparib for mutated mcrpc | gerhardt attard
-
2:41
rob's prostate cancer story and successful treatment with abiraterone
-
3:00
olaparib and adavosertib, work best when given sequentially in patients with advanced tumours
-
5:19
xtandi patient stories
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
5:17
abiraterone alone likely suppresses testosterone sufficiently in mcrpc patients | carsten ohlmann
-
5:59
peace-1 points to benefit of adding abiraterone to adt–docetaxel in de novo mcspc | karim fizazi
-
3:02
charles ryan, md: treatment options and favorable approaches for an elderly patient
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:55
arto: abiraterone acetate plus sbrt for crpc
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
4:30
profound: olaparib for hrr mcrpc
-
4:25
chemotherapy versus abiraterone acetate in mhspca
-
1:17
abiraterone for the treatment of cn1 prostate cancer